blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3030256

EP3030256 - NDP-MSH FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS [Right-click to bookmark this link]
Former [2016/24]NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CNS
[2019/26]
StatusThe patent has been granted
Status updated on  22.12.2023
Database last updated on 02.11.2024
FormerGrant of patent is intended
Status updated on  07.07.2019
FormerExamination is in progress
Status updated on  02.02.2018
Most recent event   Tooltip01.11.2024Lapse of the patent in a contracting state
New state(s): RO, SK		published on 04.12.2024 [2024/49]
Applicant(s)For all designated states
Clinuvel Pharmaceuticals Ltd.
Level 11, 535 Bourke Street
Melbourne, Victoria 3000 / AU
[2024/03]
Former [2016/24]For all designated states
Westfälische Wilhelms-Universität Münster
Schlossplatz 2
48149 Münster / DE
Inventor(s)01 / LUGER, Thomas A.
Langemarckstrasse 64
48147 Muenster / DE
02 / LOSER, Karin
Franziskanerinnenweg 16
48341 Altenberge / DE
03 / WOLGEN, Philippe
Melbourne Victoria 3000 / AU
 [2024/04]
Former [2016/24]01 / LUGER, Thomas A.
Langemarckstrasse 64
48147 Muenster / DE
02 / LOSER, Karin
Franziskanerinnenweg 16
48341 Altenberge / DE
Representative(s)Farago-Schauer, Peter Andreas
Farago Patentanwälte
Steinsdorfstraße 14
80538 München / DE
[2024/04]
Former [2016/24]Schiweck, Weinzierl & Koch
European Patent Attorneys
Landsberger Straße 98
80339 München / DE
Application number, filing date14758791.905.08.2014
[2016/24]
WO2014EP66816
Priority number, dateEP2013000390905.08.2013         Original published format: EP 13003909
EP2013017991109.08.2013         Original published format: EP 13179911
[2016/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015018827
Date:12.02.2015
Language:EN
[2015/06]
Type: A1 Application with search report 
No.:EP3030256
Date:15.06.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 12.02.2015 takes the place of the publication of the European patent application.
[2016/24]
Type: B1 Patent specification 
No.:EP3030256
Date:24.01.2024
Language:EN
[2024/04]
Search report(s)International search report - published on:EP12.02.2015
ClassificationIPC:A61K38/34, A61P25/28
[2016/24]
CPC:
A61K38/34 (EP,US); A61K45/06 (US); A61K9/0019 (US);
A61P25/28 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NDP-MSH ZUR VERWENDUNG IN DER BEHANDLUNG VON MULTIPLE SKLEROSE[2019/26]
English:NDP-MSH FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS[2019/26]
French:NDP-MSH POUR L'UTILISATION DANS LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES[2019/26]
Former [2016/24]NDP-MSH ZUR BEHANDLUNG VON ENTZÜNDLICHEN UND/ODER NEURODEGENERATIVEN ERKRANKUNGEN DES ZENTRALEN NERVENSYSTEMS
Former [2016/24]NDP-MSH FOR TREATMENT OF INFLAMMATORY AND/OR NEURODEGENERATIVE DISORDERS OF THE CNS
Former [2016/24]NDP-MSH POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET/OU NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL (SNC)
Entry into regional phase02.03.2016National basic fee paid 
02.03.2016Designation fee(s) paid 
02.03.2016Examination fee paid 
Examination procedure02.03.2016Examination requested  [2016/24]
23.09.2016Amendment by applicant (claims and/or description)
05.02.2018Despatch of a communication from the examining division (Time limit: M06)
11.09.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
21.11.2018Reply to a communication from the examining division
05.02.2019Observations by third parties
08.07.2019Communication of intention to grant the patent
16.10.2019Observations by third parties
17.10.2019Observations by third parties
15.11.2019Fee for grant paid
15.11.2019Fee for publishing/printing paid
15.11.2019Receipt of the translation of the claim(s)
15.11.2019Observations by third parties
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
21.11.2018Request for further processing filed
21.11.2018Full payment received (date of receipt of payment)
Request granted
03.12.2018Decision despatched
Fees paidRenewal fee
22.08.2016Renewal fee patent year 03
22.08.2017Renewal fee patent year 04
28.08.2018Renewal fee patent year 05
26.08.2019Renewal fee patent year 06
20.08.2020Renewal fee patent year 07
23.08.2021Renewal fee patent year 08
25.08.2022Renewal fee patent year 09
25.08.2023Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Stay/Interruption18.12.2019Stay of proceedings[2020/07]
18.12.2019Stay of proceedings[2023/40]
01.12.2023Resumption of proceedings[2023/40]
Lapses during opposition  TooltipAT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
[2024/49]
Former [2024/48]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/47]AT24.01.2024
BG24.01.2024
DK24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/37]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/36]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/35]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
NL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
Former [2024/34]BG24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
NL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
Former [2024/33]LT24.01.2024
NL24.01.2024
NO24.04.2024
IS24.05.2024
Former [2024/32]NL24.01.2024
IS24.05.2024
Former [2024/31]NL24.01.2024
Cited inInternational search[AD]US7807143  (BROD STALEY A [US]) [AD] 1-15* abstract *;
 [IDA]  - CARNIGLIA LILA ET AL, "Effect of NDP-[alpha]-MSH on PPAR-[gamma] and -[beta] expression and anti-inflammatory cytokine release in rat astrocytes and microglia.", PLOS ONE, (20130226), vol. 8, no. 2, ISSN 1932-6203, pages 1 - 11, XP002713755 [ID] 1,3-11,13,15 * abstract * [A] 2,12,14

DOI:   http://dx.doi.org/10.1371/journal.pone.0057313
 [A]  - TER LAAK MARIEL P ET AL, "The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, (20030221), vol. 462, no. 1-3, doi:10.1016/S0014-2999(02)02945-X, ISSN 0014-2999, pages 179 - 183, XP002542030 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1016/S0014-2999(02)02945-X
 [XA]  - CATANIA ET AL, "Neuroprotective actions of melanocortins: a therapeutic opportunity", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 31, no. 7, doi:10.1016/J.TINS.2008.04.002, ISSN 0166-2236, (20080701), pages 353 - 360, (20080610), XP022794923 [X] 1,3-11,13,15 * table 3 * [A] 2,12,14

DOI:   http://dx.doi.org/10.1016/j.tins.2008.04.002
otherIT1406071
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.